Compare Fox Corp Class B (FOX) vs Novavax Inc (NVAX) Price & Performance

Fox Corporation (FOX) trades at $51.06, up 3.15% with strong recent earnings beats. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Fundamentally, the company delivered robust 2025 results with $16.3B revenue and $2.26B net income, supported by improved cash flow generation. Recent news highlights Fox's strategic positioning in streaming and advertising growth.

Fox presents a compelling value opportunity with reasonable valuation multiples (P/E 13.26, P/S 1.39) and consistent earnings outperformance. However, technical weakness and competitive pressures in media streaming require monitoring. Analyst consensus leans positive with 42.86% buy ratings, though execution risks in the Roku integration and advertising market volatility remain key considerations.

Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.

The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.